Showing 1 - 20 results of 131 for search '"диабетический макулярный отек"', query time: 0.82s Refine Results
  1. 1
    Academic Journal

    Source: Ophthalmology in Russia; Том 22, № 1 (2025); 54-62 ; Офтальмология; Том 22, № 1 (2025); 54-62 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2025-1

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/2578/1300; Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12):1221–1234. doi:10.1016/S2214-109X(17)30393-5.; Bikbov MM, Fayzrakhmanov RR, Kazakbaeva GM, Zainullin RM, Arslangareeva II, Gilmanshin TR, Salavatova VF, Nikitin NA, Mukhamadieva SR, Yakupova DF, Khikmatullin RI, Zaynetdinov AF, Uzianbaeva YV, Aminev SK, Nuriev IF, Jonas JB. Prevalence, awareness and control of diabetes in Russia: The Ural Eye and Medical Study on adults aged 40+ years. PLoS One. 2019;14(4):e0215636. doi:10.1371/journal.pone.0215636.; Клинические рекомендации. Сахарный диабет: диабетическая ретинопатия, диабетический макулярный отек (дата обращения: 11.09.2023).; Петрачков, ДВ, Филиппов ВМ, Алхарки Л. Сравнительный анализ результатов хирургического лечения диабетической ретинопатии у пациентов с различными типами сахарного диабета. Офтальмология. Восточная Европа. 2022;12(4):435–447.; Nishi K, Nishitsuka K, Yamamoto T, Yamashita H. Factors correlated with visual outcomes at two and four years after vitreous surgery for proliferative diabetic retinopathy. PLoS One. 2021 Jan 14;16(1):e0244281. doi:10.1371/journal.pone.0244281.; Yau GL, Silva PS, Arrigg PG, Sun JK. Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. Semin Ophthalmol. 2018;33(1):126–133. doi:10.1080/08820538.2017.1353832.; Велиева ИА. К вопросу о причинах прогрессирования диабетической ретинопатии после выполнения панретинальной лазерной коагуляции. Офтальмология. Восточная Европа. 2022;12(2):218–225.; Шишкин ММ, Сафарли НН, Касатикова ЕВ, Антонюк СВ. Щадящая витреоретинальная хирургия при далекозашедшей пролиферативной диабетической ретинопатии: обоснование, техника, отдаленные результаты. Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2009;4(2):23–28.; Шишкин ММ, Юлдашева НМ. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии. Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2011;6(1):77–81.; Петрачков ДВ, Будзинская МВ, Матющенко АГ, Сидамонидзе АЛ, Филиппов ВМ. Вискодиссекция с контрастированием эпиретинальных мембран в хирургии пролиферативной диабетической ретинопатии. Вестник офтальмологии. 2021;137(4):18–23.; Nisic F, Jovanovic N, Mavija M, Alimanovic-Halilovic E, Nisic A, Lepara O, Cemerlic A. Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy. Arch Med Sci. 2019 Mar;15(2):449–456. doi:10.5114/aoms.2018.73208.; Pei M, Zhao X, Wan G. A systematic review and meta-analysis of clinical outcomes of small gauge vitrectomy with or without intravitreal antivascular endothelial growth factor agents pretreatment for proliferative diabetic retinopathy. Ophthalmic Res. 2023 Mar 27. doi:10.1159/000530231.; Patel V, Rohowetz LJ, Pakravan P, Kalavar M, Yannuzzi NA, Sridhar J. Outcomes of Pars Plana Vitrectomy with Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy Without Retinal Detachment: A Seven-Year Retrospective Study. Clin Ophthalmol. 2023 Feb 1;17:471–478. doi:10.2147/OPTH.S400474.; Tan Y, Fukutomi A, Sun MT, Durkin S, Gilhotra J, Chan WO. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review. Surv Ophthalmol. 2021 Nov-Dec;66(6):926–932. doi:10.1016/j.survophthal.2021.03.001.; Петрачков ДВ, Барышев КВ, Филиппов ВМ. Анализ геморрагических осложнений в хирургии пролиферативной диабетической ретинопатии. Современные технологии в офтальмологии. 2022;1(41):108–113.; Shimura M, Yasuda K, Nakazawa T, Abe T, Shiono T, Iida T, Sakamoto T, Nishida K. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009 Dec;247(12):1617–1624. doi:10.1007/s00417-009-1147-x.; Mukhtar A, Khan MS, Junejo M, Ishaq M, Akbar B. Effect of pan retinal photocoagulation on central macular thickness and visual acuity in proliferative diabetic retinopathy. Pak J Med Sci. 2016 Jan-Feb;32(1):221–224. doi:10.12669/pjms.321.8758.; Серпик ВГ, Арсютов ДГ, Гулидова ЕГ, Золотарев АВ, Исхакова АГ, Куликов АЮ, Целина МЭ, Ягудина РИ. Экономические аспекты лечения диабетического макулярного отека на региональном уровне в Российской Федерации. Вестник офтальмологии. 2017;133(6):138–148.; Shroff CM, Gupta C, Shroff D, Atri N, Gupta P, Dutta R. Bimanual microincision vitreous surgery for severe proliferative diabetic retinopathy: outcome in more than 300 eyes. Retina. 2018 Sep;38 Suppl 1:S134–S145. doi:10.1097/IAE.0000000000002093.; Gershoni A, Barayev E, Jbara D, Hadayer A, Axer-Siegel R, Dotan A, Gal-Or O, Tuuminen R, Ehrlich R. Postoperative complications of combined phacoemulsification and pars plana vitrectomy in diabetic retinopathy patients. Front Med (Lausanne). 2022 Sep 30;9:978346. doi:10.3389/fmed.2022.978346.; Петрачков ДВ, Барышев КВ, Аржуханов ДД. Влияние интраоперационной панретинальной лазеркоагуляции сетчатки на морфометрические показатели макулярной области у пациентов с диабетической ретинопатией в ранние сроки наблюдения. Саратовский научно-медицинский журнал. 2021;2(17):356–361.; Damian I, Nicoară SD. Visual outcomes and prognostic factors following 23G vitrectomy for vitreous hemorrhage in eyes with proliferative diabetic retinopathy. Arq Bras Oftalmol. 2023 Mar-Apr;86(2):105–112. doi:10.5935/0004-2749.20230037.; Гамидов АА, Сурнина ЗВ, Андреева ИВ. Тактика комбинированного (ANTIVEGF и лазерного) лечения вторичной оперированной рефрактерной неоваскулярной глаукомы (клиническое наблюдение). Медицинский совет. 2021;12:374–378.; Sun D, Lin Y, Zeng R, Yang Z, Deng X, Lan Y. The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy. Eur J Ophthalmol. 2021 Nov;31(6):3057–3067. doi:10.1177/1120672120980686.; https://www.ophthalmojournal.com/opht/article/view/2578

  2. 2
  3. 3
    Academic Journal
  4. 4
  5. 5
  6. 6
    Academic Journal

    Source: Ophthalmology in Russia; Том 20, № 4 (2023); 704-707 ; Офтальмология; Том 20, № 4 (2023); 704-707 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2023-4

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/2240/1166; Шадричев Ф.Е., Астахов Ю.С., Григорьева Н.Н. Эпидемиологические аспекты поражения сетчатки при сахарном диабете (результаты скрининга диабетической ретинопатии в Санкт-Петербурге). Офтальмологические ведомости. 2009;2(4):13–18.; Porta M., Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther. 2004 Aug;103(2):167–177. doi:10.1016/j.pharmthera.2004.07.001; Stratton I.M., Kohner E.M., Aldington S.J. UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia. 2001 Feb;44(2):156–163. doi:10.1007/s001250051594.; Величко П.Б. Комбинированное лечение диабетического макулярного отека. Современные технологии лечения витреоретинальной патологии. 2015;1:43–45.; Patz A., Schatz H., Berkow J.W. Macular edema—an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 1973 JanFeb;77(1):OP34–42; Петрачков Д.В., Будзинская М.В., Барышев К.В. Современные возможности визуализации периферических отделов сетчатки при диабетической ретинопатии. Вестник офтальмологии. 2020;136(4):272–278. doi:10.17116/oftalma2020136042272; Boyer D.S., Yoon Y.H., Belfort R. Jr.; Ozurdex MEAD Study Group. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024.; Файзрахманов Р.Р. Озурдекс в терапии диабетического макулярного отека. Когда назначать? Вестник офтальмологии. 2019;135(4):121–127 doi:10.17116/oftalma2019135041121.; https://www.ophthalmojournal.com/opht/article/view/2240

  7. 7
    Academic Journal

    Source: Ophthalmology in Russia; Том 20, № 4 (2023); 753-760 ; Офтальмология; Том 20, № 4 (2023); 753-760 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2023-4

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/2247/1173; Братчикова Н.А., Желнина А.И., Лопатин Д.В., Сивакова Л.В. сахарный диабет: этиология, патогенез, терапия. Международный студенческий научный вестник. 2020:1. URL: https://eduherald.ru/ru/article/view?id=19902 (дата обращения: 13.10.2023).; Демидова Т.Ю., Кожевников А.А. Диабетическая ретинопатия: история, современные подходы к ведению, перспективные взгляды на профилактику и лечение. Сахарный диабет. 2020;23(1):95–105. doi:10.14341/DM10273.; Diabetes and the Eye: Latest Concepts and Practices. Eds: D.R. Lazzaro, S.I. McFarlane. 2021;249. Online Store. doi:10.2174/97898114664651210201.; Kuo BL, Singh RP. Brolucizumab for the treatment of diabetic macular edema. Curr Opin Ophthalmol. 2022 May 1;33(3):167–173. doi:10.1097/ICU.0000000000000849.; Клинические рекомендации «Сахарный диабет: ретинопатия диабетическая, макулярный отек диабетический» (возрастная категория: взрослые; ID 115). М., 2023. URL: https://cr.minzdrav.gov.ru/schema/115_2?ysclid=lnm2lnkim147038460; Юсеф Наим Юсеф, Будзинская М.В. Базовые принципы антиангиогенной терапии заболеваний глазного дна: учебное пособие; Казань: Логос-Пресс, 2023. 368 с.; Куликов А.Н., Малафеева А.Ю., Калиничева Я.А., Мальцев Д.С., Жалимова В.Р., Васильев А.С. Краткосрочный опыт применения бролуцизумаба в лечении диабетического макулярного отека. Вестник офтальмологии. 2023;139(1):99–105. doi:10.17116/oftalma202313901199.; https://www.ophthalmojournal.com/opht/article/view/2247

  8. 8
    Academic Journal

    Source: Clinical Endocrinology and Endocrine Surgery; № 2 (2019); 46-54
    Клиническая эндокринология и эндокринная хирургия; № 2 (2019); 46-54
    Клінічна ендокринологія та ендокринна хірургія; № 2 (2019); 46-54

    File Description: application/pdf

  9. 9
    Academic Journal

    Source: Ophthalmology in Russia; Том 19, № 4 (2022); 734-739 ; Офтальмология; Том 19, № 4 (2022); 734-739 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2022-4

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/1977/1037; Сахарный диабет в цифрах: действительность и прогнозы. Управление Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека по Тамбовской области, 2022. URL: http://68.rospotrebnadzor.ru/content/545/21700/; Okonkwo O.N., Akanbi T., Agweye C.T. Current Management of Diabetic Macular Edema. In (Ed.), Diabetic Eye Disease — From Therapeutic Pipeline to the Real World. IntechOpen. 2022. DOI:10.5772/intechopen.100157; Deák G.G., Bolz M., Ritter M., Prager S., Benesch T., Schmidt Erfurth U.; Diabetic Retinopathy Research Group Vienna. A systematic correlation between morphology and functional alterations in diabetic macular edema. Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6710–6714. DOI:10.1167/iovs.09 5064; Yoshitake T., Murakami T., Suzuma K. Hyperreflective Foci in the Outer Retinal Layers as a Predictor of the Functional Efficacy of Ranibizumab for Diabetic Macular Edema. Sci Rep. 2020;10:873. DOI:10.1038/s41598-020-57646-y; Ehlers J.P., Uchida A., Hu M., Figueiredo N., Kaiser P.K., Heier J.S., Brown D.M., Boyer D.S., Do D.V., Gibson A., Saroj N., Srivastava S.K. Higher Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index. Ophthalmol Retina. 2019 Dec;3(12):1056–1066. DOI:10.1016/j.oret.2019.06.010; Шеремет Н.Л., Шмелькова М.С., Андреева Н.А., Жоржоладзе Н.В., Фомин А.В., Крылова Т.Д., Цыганкова П.Г. Особенности микрососудистых изменений сетчатки и зрительного нерва у пациентов с наследственной оптической нейропатией по данным оптической когерентной томографии ангиографии. Вестник офтальмологии. 2020;136(4 2):171–182. DOI:10.17116/oftalma2020136042171; Аржуханов Д.Д., Петрачков Д.В., Матющенко А.Г. Влияние толщины и сосудистой плотности сетчатки на ее светочувствительность при диабетическом макулярном отеке. Точка зрения. Восток — Запад. 2021;2:37–40. DOI:10.25276/2410-1257-2021-2-37-40; Sophie R., Lu N., Campochiaro P.A. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. Ophthalmology. 2015 Jul;122(7):1395–1401. DOI:10.1016/j.ophtha.2015.02.036; Roberts P.K. Quantification of fluid resolution and visual acuity gain in patients with diabetic macular edema using deep learning: A post hoc analysis of a randomized clinical trial. JAMA ophthalmology. 2020;138.9:945–953. DOI:10.1001/jamaophthalmol.2020.2457; Daruich A. Mechanisms of macular edema: beyond the surface. Progress in retinal and eye research. 2018;63:20–68. DOI:10.1016/j.preteyeres.2017.10.006; Дуржинская М.Х. Микроаневризмы как маркер диабетической ретинопатии. Вестник офтальмологии. 2021;137(5 2):300–305. DOI:10.17116/oftalma2021137052300; Campochiaro P.A., Choy D.F., Do D.V., Hafiz G., Shah S.M., Nguyen Q.D., Rubio R., Arron J.R. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009 Nov;116(11):2158–2164. DOI:10.1016/j.ophtha.2009.04.038; Hinkle O., HSU J. The Future Looks Bright: The Therapeutics Pipeline for Diabetic Retinopathy. Retina today. 2020. Nov/Dec:38–40.; Brown D.M., Emanuelli A, Bandello F., Barranco J.J.E., Figueira J, Souied E., Wolf S., Gupta V., Ngah N.F., Liew G., Tuli R., Tadayoni R., Dhoot D., Wang L., Bouillaud E., Wang Y., Kovacic L., Guerard N., Garweg J.G. KESTREL and KITE: 52 Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022 Jun;238:157–172. DOI:10.1016/j.ajo.2022.01.004; https://www.ophthalmojournal.com/opht/article/view/1977

  10. 10
  11. 11
    Academic Journal

    Source: Ophthalmology in Russia; Том 18, № 3S (2021); 718-726 ; Офтальмология; Том 18, № 3S (2021); 718-726 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2021-3S

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/1649/890; International Diabetes Federation. IDF Diabetes Atlas. 9th ed; 2019.; Lee R., Wong T.Y., Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17. DOI:10.1186/s40662-015-0026-2; WHO. Global Report on Diabetes; 2016:88. https://www.who.int/publications/i/item/9789241565257; Yau J., Rogers S., Kawasaki R. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564. DOI:10.2337/dc11-1909; International Diabetes Federation. IDF Diabetes Atlas. 8th ed. Brussels:IDF; 2017.; Липатов Д.В., Викулова О.К., Железнякова А.В. Эпидемиология диабетической ретинопатии в Российской Федерации по данным федерального регистра пациентов с сахарным диабетом (2013–2016 гг.). Сахарный диабет. 2018;21(4):230–240. DOI:10.14341/DM9797; Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Сахарный диабет. 2017;20(1S):1–121. DOI:10.14341/DM20171S8; Maniadakis N., Konstantakopoulou E. Cost effectiveness of treatments for diabetic retinopathy: a systematic literature review. PharmacoEconomics. 2019;37(8):995– 1010. Accessed April 22, 2019. DOI:10.1007/s40273-019-00800-w; Здравоохранение в России. Под ред. Шаповала И.Н., Никитиной С.Ю. М.: Росстат; 2019.; Дедов И.И., Шестакова М.В., Викулова О.К. Эпидемиология сахарного диабета в Российской Федерации: клинико-статистический анализ по данным Федерального регистра сахарного диабета. Сахарный диабет. 2017;20(1):13–41. DOI:10.14341/DM8664; Simo-Servat O., Hernandez C., Simo R. Diabetic retinopathy in the context of patients with diabetes. Ophthalmic Research. 2019;62(4):211–217. DOI:10.1159/000499541; Ивахненко О.И., Нероев В.В., Зайцева О.В. Возрастная макулярная дегенерация и диабетическое поражение глаз. Социально-экономические аспекты заболеваемости. Вестник офтальмологии. 2021;137(1):123–129. DOI:10.17116/oftalma2021137011123; Stitt A., Curtis T., Chen M. The progress in understanding and treatment of diabetic retinopathy. Progress in Retinal and Eye Research. 2016;51:156–186. DOI:10.1016/j.preteyeres.2015.08.001; Ting D., Cheung G., Wong T. Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review. Clinical & Experimental Ophthalmology. 2016;44(4):260–277. DOI:10.1111/ceo.12696; Mansour S., Browning D., Wong K. The Evolving Treatment of Diabetic Retinopathy. Clinical Ophthalmology. 2020;14:653–678. Accessed March 19, 2020. DOI:10.2147/OPTH.S236637; Gupta V., Fernando J. Arevalo. Surgical Management of Diabetic Retinopathy. Middle East African Journal of Ophthalmology. 2013;20(4):283–292. DOI:10.410309749233.120003; Lin J., Chang J., Yannuzzi N. Cost Evaluation of Early Vitrectomy versus Panretinal Photocoagulation and Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy. Ophthalmology. 2018;125(9):1393–1400. DOI:10.1016/j.ophtha.2018.02.038; Nawaza I., Rezzolaa S., Cancarini A. Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Progress in Retinal and Eye Research. 2019;72:100756. DOI:10.1016/j.preteyeres.2019.03.002; The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90(2):121–125. DOI:10.1016/s0161-6420(83)34588-7; Hernández C., Simó-Servat A., Bogdanov P., Simó R. Diabetic retinopathy: new therapeutic perspectives based on pathogenic mechanisms. Journal of Endocrinological Investigation. 2017;40(9):925–935. DOI:10.1007/s40618-017-0648-4; Van Geest R., Lesnik-Oberstein S., Tan H. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(4):587–590. DOI:10.1136/bjophthalmol-2011-301005; Балашевич Л.И., Измайлова А.С. Диабетическая офтальмопатия. СПб.: Человек; 2012.; Cunha-Vaz J. Mechanisms of retinal fluid accumulation and blood-retinal barrier breakdown. Dev. Ophthalmol. 2017;58:11–20. DOI:10.1159/000455265; Coscas G., Cunha-Vaz J., Soubrane G. Macular edema: defnition and basic concepts. Dev. Ophthalmol. 2017;58:1–10. DOI:10.1159/000455264; Zhang X., Zeng H., Bao S. Diabetic macular edema: new concepts in pathophysiology and treatment. Cell Biosci. 2014;4:27. Accessed May 14, 2014. DOI:10.1186/2045-3701-4-27; Daruich A., Matet A., Moulin A. Mechanisms of macular edema: beyond the surface. Prog. Retin. Eye Res. 2018;63:20–68. DOI:10.1016/j.preteyeres.2017.10.006; The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. American Journal of Ophthalmology. 1976;81:383–396. DOI:10.1016/0002-9394(76)90292-0; Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98(5Suppl):766–785. DOI:10.1016/S0161-6420 (13)38011-7; Suzuki Y., Adachi K., Maeda N. Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative infammation. International Journal of Retina and Vitreous. 2020;6:24. Accessed June 8, 2020. DOI:10.1186/s40942-020-00222-3; Будзинская М.В., Плюхова А.А., Торопыгин С.Г. Современный взгляд на лечение экссудативной формы возрастной макулярной дегенерации. Вестник офтальмологии. 2019;135(5):107–115. DOI:10.17116/oftalma2019135051107; Ip M.S., Domalpally A., Sun J.K., Ehrlich J.S. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and base-line risk factors for worsening retinopathy. Ophthalmology. 2015;122(2):367–374. DOI:10.1016/j.ophtha.2014.08.048; Bressler S., Odia I., Glassman A. Changes in diabetic retinopathy severity when treating diabetic macular edema with ranibizumab: DRCR. Net protocol I 5-year report. Retina. 2018;38(10):1896–1904. DOI:10.1097/IAE.0000000000002302; Wang D., Zhao X., Zhang W. Perioperative anti‑vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Scientifc Reports. 2020;10(1):18880. Accessed November 3, 2020. DOI: /10.1038/s41598-020-75896-8; Tan Y., Fukutomi A., Sun M. Anti-VEGF Crunch Syndrome in Proliferative Diabetic Retinopathy: A Review. Surv Ophthalmol. 2021;S0039-6257(21)00074-6. Accessed March 8, 2021. DOI:10.1016/j.survophthal.2021.03.001; Jiang T., Gu J., Zhang P. The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study. BMC Ophthalmol. 2020;20(1):43. DOI:10.1186/s12886-020-1321-9; Antoszyk A., Glassman A., Beaulieu W. DRCR Retina Network. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A Randomized Clinical Trial. JAMA. 2020;324(23):2383–2395. DOI:10.1001/jama.2020.23027; Maturi R., Glassman A., Liu D. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol. 2018;136(1):29–38. DOI:10.1001/jamaophthalmol.2017.4914; Iglicki M., Zur D., Busch C. Progression of diabetic retinopathy severity after treatment with dexamethasone implant: a 24-month cohort study the ‘DR-Pro-DEX Study’. Acta Diabetol. 2018;55:541–547. DOI:10.1007/s00592-018-1117-z; Wykoff C., Chakravarthy U., Campochiaro P. Long-term effects of intravitreal 0.19 mg fluocinolone acetonide implant on progression and regression of diabetic retinopathy. Ophthalmology. 2017;124(4):440–449. DOI:10.1016/j.ophtha.2016.11.034; Pessoa B., Coelho J., Correia N. Fluocinolone acetonide intravitreal implant 190 mug (ILUVIEN(R)) in vitrectomized versus nonvitrectomized eyes for the treatment of chronic diabetic macular edema. Ophthalmic Res. 2018;59(2):68–75. DOI:10.1159/000484091; Gross J., Glassman A., Jampol L. Writing Committee for the Diabetic Retinopathy Clinical Research N. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146. DOI:10.1001/jama.2015.15217; Wubben T., Johnson M. Anti-VEGF Treatment Interruption Study Group. AntiVEGF therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13–18. DOI:10.1016/j.ajo.2019.03.005; Machemer R., Buettner H., Norton E., Parel J. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol. 1971;75(4):813–820.; Khan M., Kuley A., Riemann C. Long-term visual outcomes and safety profile of 27-gauge pars plana vitrectomy for posterior segment disease. Ophthalmology. 2018;125(3):423–431. DOI:10.1016/j.ophtha.2017.09.013; Yokota R., Inoue M., Itoh Y. Comparison of microinsicion vitrectomy and conventional 20-gauge vitrectomy for severe proliferative diabetic retinopathy. Jpn J Ophthalmol. 2015;59(5):288–294. DOI:10.1007/s10384-015-0396-y; Rizzo S., Fantoni G., Mucciolo D. Ultrasound in vitrectomy an alternative approach to traditional vitrectomy techniques. Retina. 2020;40(1):24–32. DOI:10.1097/IAE.0000000000002354; Berrocal M., Acaba L., Chenworth M. Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy. Current Diabetes Reports. 2019;19(10):106. Accessed September 16, 2019. DOI:10.1007/s11892-019-1210-x; Smiddy W., Flynn H. Vitrectomy in the management of diabetic retinopathy. Surv Ophthalmol. 1999;43(6):491–507. DOI:10.1016/s0039-6257(99)00036-3; The Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol. 1985;103:1644–1652.; Browning D., Lee C., Stewart M., Landers M. Vitrectomy for center-involved diabetic macular edema. Clin Ophthalmol. 2016;10:735–742. DOI:10.2147/OPTH.S104906; Silva P., Diala P., Hamam R. Visual outcomes from pars plana vitrectomy versus combined pars plana vitrectomy, phacoemulsification, and intraocular lens implantation in patients with diabetes. Retina. 2014;34(10):1960–1968. DOI:10.1097/IAE.0000000000000171; Sharma T., Fong A., Lai T. Surgical treatment for diabetic vitreoretinal diseases: a review. Clin Exp Ophthalmol. 2016;44(4):340–354. DOI:10.1111/ceo.12752; Коновалова К.И., Шишикин М.М., Файзрахманов Р.Р. Эффективность многоэтапного хирургического лечения диабетической ретинопатии, осложненной начальной катарактой. Вестник офтальмологии. 2020;136(6-2):171–176. DOI:10.17116/oftalma2020136062171; Gupta B., Sivaprasad S., Wong R. Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: The Drive UK study. Eye (Lond). 2012;26:510–516. DOI:10.1038/eye.2011.321; Iyer S., Regan K., Burnham J. Surgical management of diabetic tractional retinal detachments. Surv Ophthalmol. 2019;64(6):780–809. DOI:10.1016/j.survophthal.2019.04.008; Stewart M., Browning D., Landers M. Current management of diabetic tractional retinal detachments. Indian J Ophthalmol. 2018;66(12):1751–1762. DOI:10.4103/ijo.IJO_1217_18; Kikushima W., Imai A., Hirano T. Quick Referral and Urgent Surgery to Preempt Foveal Detachment in Retinal Detachment Repair. Asia Pac J of Ophthalmol. 2014;3(3):141–145. DOI:10.1097/APO.0b013e3182a81240; Brănişteanu D., Bilha A., Moraru A. Vitrectomy surgery of diabetic retinopathy complications. Rom J Ophthalmol. 2016;60(1):31–36.; Hu X., Liu H., Wang L. Efficacy and safety of vitrectomy with internal limiting membrane peeling for diabetic macular edema: a meta-analysis. Int J Ophthalmol. 2018;11(11):1848–1855. DOI:10.18240/ijo.2018.11.18; Jackson T., Nicod E., Angelis A. Pars plana vitrectomy for diabetic macular edema. A Systematic Review, Meta-Analysis, and Synthesis of Safety Literature. Retina. 2017;37(5):886–895. DOI:10.1097/IAE.0000000000001280; Simunovic M., Hunyor A., Ho I. Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol. 2014;49(2):188–195. DOI:10.1016/j.jcjo.2013.11.012; Adelman R., Parnes A., Michalewska Z. Strategy for the management of diabetic macular edema: the European vitreo-retinal society macular edema study. BioMed Research International. 2015; 2015:352487. DOI:10.1155/2015/352487; Farouk M., Naito T., Sayed K. Outcomes of 25-gauge vitrectomy for proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2011;249:369–376. DOI:10.1007/s00417-010-1506-7; Chen W., Lin C., Ko P. In vivo confocal microscopic findings of corneal wound healing after corneal epithelial debridement in diabetic vitrectomy. Ophthalmology. 2009;116:1038–1047. DOI:10.1016/j.ophtha.2009.01.002; Holekamp N., Bai F., Shui Y. Ischemic diabetic retinopathy may protect against nuclear sclerotic cataract. Am J Ophthalmol. 2010;150(4):543–550. DOI:10.1016/j.ajo.2010.05.013; Khuthaila M., Hsu J., Chiang A. Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy. Am J Ophthalmol. 2013;155(4):757–763. DOI:10.1016/j.ajo.2012.11.004; Lee B., Yu H. Vitreous hemorrhage after the 25-gauge transconjunctival sutureless vitrectomy for proliferative diabetic retinopathy. Retina. 2010;30(10):1671–1677. DOI:10.1097/IAE.0b013e3181dcfb79; Jackson T., Johnston R., Donachie P. The Royal College of Ophthalmologists’ national ophthalmology database study of vitreoretinal surgery: Report 6, diabetic vitrectomy. JAMA Ophthalmology. 2016;134(1):79–85. DOI:10.1001/jamaophthalmol.2015.4587; Ehrlich R., Goh Y., Ahmad N., Polkinghorne P. Retinal breaks in small-gauge pars plana vitrectomy. Am J Ophthalmol. 2012;153(5):868–872. DOI:10.1016/j.ajo.2011.10.015; Koreen L., Yoshida N., Escariao P. Incidence of risk factors for, and combined mechanism of late-onset openangle glaucoma after vitrectomy. Retina. 2012;32(1):160– 167. DOI:10.1097/IAE.0b013e318217fffb; Lalezary M., Kim S.J., Jiramongkolchai K., Recchia F.M., Agarwal A., Sternberg J.P. Long-term trends in intraocular pressure after pars plana vitrectomy. Retina. 2011;31(4):679–685. DOI:10.1097/IAE.0b013e3181ff0d5a; Yau G., Silva P., Arrigg P. Postoperative Complications of Pars Plana Vitrectomy for Diabetic Retinal Disease. Semin Ophthalmol. 2018;33(1):126–133. DOI:10.1080/08820538.2017.1353832; Tao Y., Jiang Y., Li X. Long-term results of vitrectomy without endotamponade in proliferative diabetic retinopathy with tractional retinal detachment. Retina. 2010;30:447–451. DOI:10.1097/IAE.0b013e3181d374a5; Rodríguez M., Pérez S., Mena-Mollá S. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. Oxid Med Cell Longev. 2019;2019:4940825. DOI:10.1155/2019/4940825; Mitchell P., Bandello F., Schmidt-Erfurth U. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625. DOI:10.1016/j.ophtha.2011.01.031; Bressler S.B., Melia M., Glassman A.R. Diabetic Retinopathy Clinical Research Network. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina. 2015;35:2516–2528. DOI:10.1097/IAE.0000000000000617; Laugesen C., Ostri C., Brynskov T. Intravitreal ranibizumab for diabetic macular oedema in previously vitrectomized eyes. Acta Ophthalmol. 2017;95(1):28–32. Accessed July 30, 2016. DOI:10.1111/aos.13160; Elhamid A., Mohamed A., Khattab A. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial. BMC Ophthalmol. 2020;20(1):130. Accessed April 6, 2020. DOI:10.1186/s12886-020-01401-4; https://www.ophthalmojournal.com/opht/article/view/1649

  12. 12
    Academic Journal

    Source: Ophthalmology in Russia; Том 18, № 3 (2021); 459-469 ; Офтальмология; Том 18, № 3 (2021); 459-469 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2021-3

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/1601/853; Cho N.H., Shaw J.E., Karuranga S., Huang Y., da Rocha Fernandes J.D., Ohlrogge A.W., Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. DOI:10.1016/j.diabres.2018.02.023; Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018;21(3):144–159. DOI:10.14341/DM9686; Khan M.A.B., Hashim M.J., King J.K., Govender R.D., Mustafa H., Al Kaabi J. Epidemiology of Type 2 Diabetes — Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health. 2020;10(1):107–111. DOI:10.2991/jegh.k.191028.001; Tóth G., Szabó D., Sándor G.L., Nagy Z.Z., Karadeniz S., Limburg H., Németh J. Diabetes and blindness in people with diabetes in Hungary. Eur J Ophthalmol. 2019;29(2):141–147. DOI:10.1177/1120672118811738; Lutski M., Shohat T., Mery N., Zucker I. Incidence and Risk Factors for Blindness in Adults with Diabetes: The Israeli National Diabetes Registry (INDR). Am J Ophthalmol. 2019;200:57–64. DOI:10.1016/j.ajo.2018.12.008; Bandello F., Battaglia Parodi M., Lanzetta P., Loewenstein A., Massin P., Menchini F., Veritti D. Diabetic Macular Edema. Dev Ophthalmol. 2017;58:102–138. DOI:10.1159/000455277; Sasongko M.B., Wardhana F.S., Febryanto G.A., Agni A.N., Supanji S., Indrayanti S.R., Widayanti T.W., Widyaputri F., Widhasari I.A., Lestari Y.D., Adriono G.A., Sovani I., Kartasasmita A.S. The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025. Br J Ophthalmol. 2020;104(4):487–492. DOI:10.1136/bjophthalmol-2019-313997; Szadkowska A., Czyżewska K., Pietrzak I., Mianowska B., Jarosz-Chobot P., Myśliwiec M. Hypoglycaemia unawareness in patients with type 1 diabetes. Pediatr Endocrinol Diabetes Metab. 2018;2018(3):126–134. DOI:10.5114/pedm.2018.80994; Lablanche S., Vantyghem M.C., Kessler L., Wojtusciszyn A., Borot S., Thivolet C., Girerd S., Bosco D., Bosson J.L., Colin C., Tetaz R., Logerot S., Kerr-Conte J., Renard E., Penfornis A., Morelon E., Buron F., Skaare K., Grguric G., Camillo-Brault C., Egelhofer H., Benomar K., Badet L., Berney T., Pattou F., Benhamou P.Y. TRIMECO trial investigators. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6(7):527–537. DOI:10.1016/S2213-8587(18)30078-0; Wat N., Wong R.L., Wong I.Y. Associations between diabetic retinopathy and systemic risk factors. Hong Kong Med J. 2016;22(6):589–599. DOI:10.12809/hkmj164869; Ghamdi A.H.A. Clinical Predictors of Diabetic Retinopathy Progression; A Systematic Review. Curr Diabetes Rev. 2020;16(3):242–247. DOI:10.2174/1573399815666190215120435; Maric-Bilkan C. Sex differences in micro- and macro-vascular complications of diabetes mellitus. Clin Sci (Lond). 2017;131(9):833–846. DOI:10.1042/CS20160998; Pescosolido N., Campagna O., Barbato A. Diabetic retinopathy and pregnancy. Int Ophthalmol. 2014;34(4):989–997. DOI:10.1007/s10792-014-9906-z; Eid S., Sas K.M., Abcouwer S.F., Feldman E.L., Gardner T.W., Pennathur S., Fort P.E. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62(9):1539–1549. DOI:10.1007/s00125-019-4959-1; Benarous R., Sasongko M.B., Qureshi S., Fenwick E., Dirani M., Wong T.Y., Lamoureux E.L. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(10):7464–7469. DOI:10.1167/iovs.11-7598; Moosaie F., Davatgari R.M., Firouzabadi F.D., Esteghamati S., Deravi N., Meysamie A., Khaloo P., Nakhjavani M., Esteghamati A. Lipoprotein(a) and Apolipo‑ proteins as Predictors for Diabetic Retinopathy and Its Severity in Adults With Type 2 Diabetes: A Case-Cohort Study. Can J Diabetes. 2020;44(5):414–421. DOI:10.1016/j.jcjd.2020.01.007; Chong Y.H., Fan Q., Tham Y.C., Gan A., Tan S.P., Tan G., Wang J.J., Mitchell P., Wong T.Y., Cheng C.Y. Type 2 Diabetes Genetic Variants and Risk of Diabetic Retinopathy. Ophthalmology. 2017;124(3):336–342. DOI:10.1016/j.ophtha.2016.11.016; Lima V.C., Cavalieri G.C., Lima M.C., Nazario N.O., Lima G.C. Risk factors for diabetic retinopathy: a case-control study. Int J Retina Vitreous. 2016;2:21. DOI:10.1186/s40942-016-0047-6; Zhu W., Wu Y., Meng Y.F., Xing Q., Tao J.J., Lu J. Association of obesity and risk of diabetic retinopathy in diabetes patients: A meta-analysis of prospective cohort studies. Medicine (Baltimore). 2018;97(32):11807. DOI:10.1097/MD.0000000000011807; Wang J., Xin X., Luo W., Wang R., Wang X., Si S., Mo M., Shao B., Wang S., Shen Y., Chen X., Yu Y. Anemia and Diabetic Kidney Disease Had Joint Effect on Diabetic Retinopathy Among Patients With Type 2 Diabetes. Invest Ophthalmol Vis Sci. 2020;61(14):25. DOI:10.1167/iovs.61.14.25; Jeng C.J., Hsieh Y.T., Yang C.M., Yang C.H., Lin C.L., Wang I.J. Development of diabetic retinopathy after cataract surgery. PLoS One. 2018;13(8):0202347. DOI:10.1371/journal.pone.0202347; Costagliola C., Romano V., De Tollis M., Aceto F., dell’Omo R., Romano M.R., Pedicino C., Semeraro F. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013;2013:629529. DOI:10.1155/2013/629529; Raczyńska D., Lisowska K.A., Pietruczuk K., Borucka J., Ślizień M., Raczyńska K., Glasner L., Witkowski J.M. The Level of Cytokines in the Vitreous Body of Severe Proliferative Diabetic Retinopathy Patients Undergoing Posterior Vitrectomy. Curr Pharm Des. 2018;24(27):3276–3281. DOI:10.2174/1381612824666180926110704; Nalini M., Raghavulu B.V., Annapurna A., Avinash P., Chandi V., Swathi N., Wasim. Correlation of various serum biomarkers with the severity of diabetic retinopathy. Diabetes Metab Syndr. 2017;11(l):451–454. DOI:10.1016/j.dsx.2017.03.034; Vujosevic S., Micera A., Bini S., Berton M., Esposito G., Midena E. Aqueous Humor Biomarkers of Müller Cell Activation in Diabetic Eyes. Invest Ophthalmol Vis Sci. 2015;56(6):3913–3918. DOI:10.1167/iovs.15-16554; Vujosevic S., Micera A., Bini S., Berton M., Esposito G., Midena E. Proteome analysis of retinal glia cells-related inflammatory cytokines in the aqueous humour of diabetic patients. Acta Ophthalmol. 2016;94(1):56–64. DOI:10.1111/aos.12812; Boss J.D., Singh P.K., Pandya H.K., Tosi J., Kim C., Tewari A., Juzych M.S., Abrams G.W., Kumar A. Assessment of Neurotrophins and Inflammatory Mediators in Vitreous of Patients With Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594–5603. DOI:10.1167/iovs.17-21973; Rusnak S., Vrzalova J., Sobotova M., Hecova L., Ricarova R., Topolcan O. The Measurement of Intraocular Biomarkers in Various Stages of Proliferative Diabetic Retinopathy Using Multiplex xMAP Technology. J Ophthalmol. 2015;2015:424783. DOI:10.1155/2015/424783; Wong T.Y., Sun J., Kawasaki R., Ruamviboonsuk P., Gupta N., Lansingh V.C., Maia M., Mathenge W., Moreker S., Muqit M.M.K., Resnikoff S., Verdaguer J., Zhao P., Ferris F., Aiello L.P., Taylor H.R. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608–1622. DOI:10.1016/j.ophtha.2018.04.007; Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. 8-й выпуск. М.: УП ПРИНТ; 2017.; Tran K., Pakzad-Vaezi K. Multimodal imaging of diabetic retinopathy. Curr Opin Ophthalmol. 2018;29(6):566–575. DOI:10.1097/ICU.0000000000000524; Cennamo G., Romano M.R., Nicoletti G., Velotti N., de Crecchio G. Optical coherence tomography angiography versus fluorescein angiography in the diagnosis of ischaemic diabetic maculopathy. Acta Ophthalmol. 2017;95(1):36–42. DOI:10.1111/aos.13159; Fan W., Nittala M.G., Fleming A., Robertson G., Uji A., Wykoff C.C., Brown D.M., van Hemert J., Ip M., Wang K., Falavarjani K.G., Singer M., Sagong M., Sadda S.R. Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography. Am J Ophthalmol. 2020;209:99–106. DOI:10.1016/j.ajo.2019.08.015; Wanek J., Blair N.P., Chau F.Y., Lim J.I., Leiderman Y.I., Shahidi M. Alterations in Retinal Layer Thickness and Reflectance at Different Stages of Diabetic Retinopathy by En Face Optical Coherence Tomography. Invest Ophthalmol Vis Sci. 2016;57(9):341–347. DOI:10.1167/iovs.15-18715; Cho Y.J., Lee D.H., Kim M. Optical coherence tomography findings predictive of response to treatment in diabetic macular edema. J Int Med Res. 2018;46(11):4455–4464. DOI:10.1177/0300060518798503; Zur D., Iglicki M., Busch C., Invernizzi A., Mariussi M., Loewenstein A., International Retina Group. OCT Biomarkers as Functional Outcome Predictors in Diabetic Macular Edema Treated with Dexamethasone Implant. Ophthalmology. 2018;125(2):267–275. DOI:10.1016/j.ophtha.2017.08.031; Kashani A.H., Chen C.L., Gahm J.K., Zheng F., Richter G.M., Rosenfeld P.J., Shi Y., Wang R.K. Optical coherence tomography angiography: A comprehensive review of current methods and clinical applications. Prog Retin Eye Res. 2017;60:66–100. DOI:10.1016/j.preteyeres.2017.07.002; Zhang A., Zhang Q., Chen C.L., Wang R.K. Methods and algorithms for optical coherence tomography-based angiography: a review and comparison. J Biomed Opt. 2015;20(10):100901. DOI:10.1117/1.JBO.20.10.100901; Spaide R.F., Klancnik J.M. Jr., Cooney M.J. Retinal vascular layers imaged by fluorescein angiography and optical coherence tomography angiography. JAMA Ophthalmol. 2015;133(1):45–50. DOI:10.1001/jamaophthalmol.2014.3616; Nesper P.L., Soetikno B.T., Zhang H.F., Fawzi A.A. OCT angiography and visiblelight OCT in diabetic retinopathy. Vision Res. 2017;139:191–203. DOI:10.1016/j.visres.2017.05.006; Li A., You J., Du C., Pan Y. Automated segmentation and quantification of OCT angiography for tracking angiogenesis progression. Biomed Opt Express. 2017;8(12):5604–5616. DOI:10.1364/BOE.8.005604; Chua J., Sim R., Tan B., Wong D., Yao X., Liu X., Ting D.S.W., Schmidl D., Ang M., Garhöfer G., Schmetterer L. Optical Coherence Tomography Angiography in Diabetes and Diabetic Retinopathy. J Clin Med. 2020;9(6):1723. DOI:10.3390/jcm9061723; OCT-Angiography Option for Mirante and RS-3000 Advance 2 AngioScan. Nidek-intl.com; 2016 [updated on February 8, 2016; cited 2021 May 22]. URL: https://www.nidek-intl.com/product/ophthaloptom/diagnostic/dia_retina/angioscan.html; Dhanireddy KK. Pancreas transplantation. Gastroenterol Clin North Am. 2012;41(1):133–142. DOI:10.1016/j.gtc.2011.12.002; Maffi P., Secchi A. Islet Transplantation Alone Versus Solitary Pancreas Transplantation: an Outcome-Driven Choice? Curr Diab Rep. 2019;19(5):26. DOI:10.1007/s11892-019-1145-2; Ramsay R.C., Goetz F.C., Sutherland D.E., Mauer S.M., Robison L.L., Cantrill H.L., Knobloch W.H., Najarian J.S. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(4):208–214. DOI:10.1056/NEJM198801283180403; Giannarelli R., Coppelli A., Sartini M.S., Aragona M., Boggi U., Mosca F., Nardi M., Del Prato S., Marchetti P. Early improvement of unstable diabetic retinopathy after solitary pancreas transplantation. Diabetes Care. 2002;25(12):2358–2359. DOI:10.2337/diacare.25.12.2358; Giannarelli R., Coppelli A., Sartini M.S., Del Chiaro M., Vistoli F., Rizzo G., Barsotti M., Del Prato S., Mosca F., Boggi U., Marchetti P. Pancreas transplant alone has beneficial effects on retinopathy in type 1 diabetic patients. Diabetologia. 2006;49(12):2977–2982. DOI:10.1007/s00125-006-0463-5; Tsai F.Y., Lau L.I., Li A.F., Chen S.J., Wang S.E., Lee F.L., Liu C.J., Shyr Y.M. Acute macular edema and peripapillary soft exudate after pancreas transplantation with accelerated progression of diabetic retinopathy. J Chin Med Assoc. 2017;80(5):319–325. DOI:10.1016/j.jcma.2017.01.004; Kim Y.J., Shin S., Han D.J., Kim Y.H., Lee J.Y., Yoon Y.H., Kim J.G. Long-term Effects of Pancreas Transplantation on Diabetic Retinopathy and Incidence and Predictive Risk Factors for Early Worsening. Transplantation. 2018;102(1):30–38. DOI:10.1097/TP.0000000000001958; https://www.ophthalmojournal.com/opht/article/view/1601

  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Academic Journal

    Source: Ophthalmology in Russia; Том 15, № 4 (2018); 463-469 ; Офтальмология; Том 15, № 4 (2018); 463-469 ; 2500-0845 ; 1816-5095 ; 10.18008/1816-5095-2018-4

    File Description: application/pdf

    Relation: https://www.ophthalmojournal.com/opht/article/view/773/544; Bourne R., Flaxman S.R., Braithwaite T., Cicinelli M.V., Das A., Jonas J.B. Vision Loss Expert Group. Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(9):e888–897.; Дедов И.И., Шестакова М.В., Сунцов Ю.И., Петеркова В.А., Галстян Г.Р., Майоров А.Ю., Кураева Т.Л., Сухарева О.Ю. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 годы». Сахарный диабет. 2013;16(2S):2–48 [Dedov I.I., Shestakova M.V., Suntsov Yu.I., Peterkova V.A., Galstjan G.R., Majorov A.Yu., Kuraeva T.L., Suhareva O.Yu. Federal targeted programme “Prevention and Management of Socially Significant Diseases (2007– 2012)”: results of the “Diabetes mellitus” sub-programme. Diabetes mellitus = Saharnyj diabet. 2013;16(2S):2–48 (In Russ.)]. DOI:10.14341/2072-0351-3879; Липатов Д.В., Александрова В.К., Атарщиков Д.С., Бессмертная Е.Г., Кон И.Л., Кузьмин А.Г., Смирнова Н.Б., Толкачева А.А., Чистяков Т.А. Эпидемиология и регистр диабетической ретинопатии в Российской Федерации. Сахарный диабет. 2014;7(1):4–7 [Lipatov D.V., Aleksandrova V.K., Atarshhikov D.S., Bessmertnaja E.G., Kon I.L., Kuz’min A.G., Smirnova N.B., Tolkacheva A.A., Chistjakov T.A. Current report from Russian Diabetic Retinopathy Register. Diabetes Mellitus = Saharnyj diabet. 2014;7(1):4–7 (In Russ.)]. DOI:10.14341/DM201414-7; Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. Сахарный диабет. 2015;18(3):5–22 [Dedov I.I., Shestakova M.V., Vikulova O.K. National register of diabetes mellitus in Russian Federation. Diabetes Mellitus = Saharnyj diabet. 2015;18(3):5–22 (In Russ.)]. DOI:10.14341/DM201535-22; Woo J., Ng W., Salah M., Neelam K., Au Eong K., Kumar C. Perioperative glycaemic control in diabetic patients undergoing cataract surgery under local anaesthesia: a survey of practices of Singapore opthalmologists and anaesthesiologists. Singapore Med J. 2016;57(2):64–68. DOI:10.11622/smedj.2016029; Pollreisz A., Schmidt-Erfurth U. Diabetic Cataract — Pathogenesis, Epidemiology and Treatment. J Ophthalmol. 2010;2010:1–8. DOI:10.1155/2010/608751; Малюгин Б.Э. Хирургия катаракты и интраокулярная коррекция на современном этапе развития офтальмохирургии. Вестник офтальмологии. 2014;6:80–88 [Malyugin B.E. State-of-the-art cataract surgery and intraocular optical correction. Annals of Ophthalmology = Vestnik oftal’mologii. 2014;6:80–88 (In Russ.)].; Draganic V., Vukosavljevic M., Petrovic N., Milivojevic M., Resan M. Evolution of cataract surgery: smaller incision — less complications. Vojnosanit Pregl. 2012;69(5):385–388.; De Silva S.R., Riaz Y., Evans J.R. Phacoemulsification with posterior chamber intraocular lens versus extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens for age-related cataract. Cochrane Database Syst Rev. 2014;1:53. DOI:10.1002/14651858.CD008812.pub2; Greenberg P.B., Tseng V.L., Wu W.C., Liu J., Jiang L., Chen C.K., Scott I.U., Friedmann P.D. Prevalence and predictors of ocular complications associated with cataract surgery in United States veterans. Ophthalmology. 2011;118(3):507–514. DOI:10.1016/j.ophtha.2010.07.023; Irvine S.R. A newly defined vitreous syndrome following cataract surgery. Am J Ophthalmol. 1953;36(5):599–619.; Daien V., Papinaud L., Domerg C., Lacombe S., Daures J., Villain M. Incidence and Characteristics of Cystoid Macular Edema after Cataract Surgery. Ophthalmology. 2016;123(3):663–664. DOI:10.1016/j.ophtha.2015.10.009; Grzybowski A., Sikorski B., Ascaso F., Huerva V. Pseudophakic cystoid macular edema: update 2016. Clin Interv Aging. 2016;11:1221–1229. DOI:10.2147/CIA.S111761; Sahin M., Cingu A.K., Gozum N. Evaluation of Cystoid Macular Edema Using Optical Coherence Tomography and Fundus Autofluorescence after Uncomplicated Phacoemulsification Surgery. J Ophthalmol. 2013;2013:1–5. DOI:10.1155/2013/376013; Tsilimbaris M.K., Tsika C., Diakonis V., Karavitaki A., Pallikaris I. Macular Edema and Cataract Surgery. Cataract Surgery. 2013;22:323–336. DOI:10.5772/765; Eriksson U., Alm A., Bjarnhall G., Granstam E., Matsson A.W. Macular edema and visual outcome following cataract surgery in patients with diabetic retinopathy and controls. Graefes Arch Clin Exp Ophthalmol. 2011;249(3):349–359. DOI:10.1007/s00417-010-1484-9; Baker C.W., Almukhtar T., Bressler N.M., Glassman A.R., Grover S., Kim S.J., Murtha T.J., Rauser M.E., Stockdale C. Diabetic Retinopathy Clinical Research Network. Macular edema after cataract surgery in eyes without preoperative centralinvolved diabetic macular edema. JAMA Ophthalmol. 2013;131(7):870–879. DOI:10.1001/jamaophthalmol.2013.2313; Liu J., Jones R.E., Zhao J., Zhang J., Zhang F. Influence of uncomplicated phacoemulsification on central macular thickness in diabetic patients: a meta-analysis. PLoS One. 2015;10(5):e0126343. DOI:10.1371/journal.pone.0126343; Yang J., Cai L., Sun Z., Ye H., Fan Q., Zhang K., Lu W., Lu Y. Risk factors for and diagnosis of pseudophakic cystoid macular edema after cataract surgery in diabetic patients. J Cataract Refract Surg. 2017;43(2):207–214. DOI:10.1016/j.jcrs.2016.11.047; Reznicek L., Kernt M., Haritoglou C. Correlation of leaking microaneurysms with retinal thickening in diabetic retinopathy. Int J Ophthalmol. 2011;4(3):269–271. DOI:10.3980/j.issn.2222-3959.2011.03.11; Худяков А.Ю., Сорокин Е.Л., Руденко В.А. Патогенетическая роль витреомакулярных тракций в формировании макулярного отека после факоэмульсификации катаракты. Дальневосточный медицинский журнал. 2011;3:72–75 [Khudyakov A.Yu., Sorokin E.L., Rudenko V.A. The peculiarities of vitreomacular interface and its role in pathogenesis of macular edema after phacoemulsification. Far East Medical Journal = Dal’nevostochnyj medicinskij zhurnal. 2011;3:72–75 (In Russ.)].; Law S., Kim E., Yu F., Caprioli J. Clinical Cystoid Macular Edema after Cataract Surgery in Glaucoma Patients. J Glaucoma. 2010;19(2):100–104. DOI:10.1097/IJG.0b013e3181a98b97; Маннанова Р.Ф., Шевчук Н.Е., Бикбулатова А.А. Значение исследования цитокинов в хирургическом лечении катаракты. Точка зрения. Восток — Запад. 2017;3:113–116 [Mannanova R.F., Shevchuk N.E., Bikbulatova A.A. The value of the study of cytokines in cataract surgical treatment. Point of View. East — West = Tochka zrenija. Vostok — Zapad. 2017;3:113–116 (In Russ.)].; Созуракова Е.А., Громакина Е.В., Шабалдин А.В., Шахматов К.С. Результаты иммунологического исследования уровня цитокинов во влаге передней камеры и сыворотке крови при оперативном лечении катаракты. Точка зрения. Восток — Запад. 2017;3:33–36 [Sozurakova E.A., Gromakina E.V., Shabaldin A.V., Shakhmatov K.S. Immunology research results cytokine levels in anterior chamber aqueous humor and blood serum during surgical treatment of cataract. Point of View. East — West = Tochka zrenija. Vostok — Zapad. 2017;3:33–36 (In Russ.)].; Орадова А.Ш., Устенова Г.О., Стабаева Г.С. Методы исследования цитокинов. MEDICINE. 2014;10:84–87 [Oradova A.Sh., Ustenova G.O., Stabaeva G.S. Methods of cytokine research. MEDICINE. 2014;10:84–87 (In Russ.)].; Zhang Y., Birru R., Di Y.P. Analysis of clinical and biological samples using microsphere-based multiplexing Luminex system. Methods Mol Biol. 2014;1105:43–57. DOI:10.1007/978-1-62703-739-6_4; Полетаев А.Б. Физиологическая иммунология (естественные аутоантитела и проблемы наномедицины). М.: Миклош, 2010. 218 с. [Poletaev A.B. Physiological immunology (natural autoantibodies and problems of nanomedicine). Moscow: Miklosh, 2010. 218 p. (In Russ.)].; Hartnett M.E., Tinkham N., Paynter L., Geisen P., Rosenberg P., Koch G., Cohen K.L. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol. 2009;148(6):895–901. DOI:10.1016/j.ajo.2009.07.014; Mitroviс S., Kelava T., Sucur A., Grcevic D. Levels of Selected Aqueous Humor Mediators (IL-10, IL-17, CCL2, VEGF, FasL) in Diabetic Cataract. Ocul Immunol Inflamm. 2016;24(2):159–166. DOI:10.3109/09273948.2014.949779; Кузьмин А.Г., Липатов Д.В., Чистяков Т.А., Смирнова О.М., Арбузова М.И., Ильин А.В., Шестакова М.В. Сосудистый эндотелиальный фактор роста в жидкости передней камеры глаза у больных диабетической ретинопатией, катарактой и неоваскулярной глаукомой. Сахарный диабет. 2010;13(3):32–36 [Kuz’min A.G., Lipatov D.V., Chistyakova T.A., Smirnova O.M., Arbuzova M.I., Ilyin A.V., Shestakova M.V. Vascular endothelial growth factor in the fluid of the anterior chamber of the eye in patients with diabetic retinopathy, cataract and neovascular glaucoma. Diabetes Mellitus = Saharnyj diabet. 2010;13(3):32–36 (In Russ.)]. DOI:10.14341/2072-0351-5485; Dong N., Xu B., Wang B., Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734–1746.; Dong N., Xu B., Chu L., Tang X. Study of 27 Aqueous Humor Cytokines in Type 2 Diabetic Patients with or without Macular Edema. PLoS One. 2015;10(4):e0125329. DOI:10.1371/journal.pone.0125329; Cheung C.M, Vania M., Ang M., Chee S.P., Li J. Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis. 2012;18:830–837.; Jonas J.B, Jonas R.A, Neumaier M., Findeisen P. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina. 2012;32(10):2150–2157. DOI:10.1097/IAE.0b013e3182576d07; Hari-Kovacs A., Lovas P., Facsko A., Crate I.D. Is second eye phacoemulsification really more painful? Wien Klin Wochenschr. 2012;124:516–519. DOI:10.1007/s00508-012-0205-2; Zhu X.J., Wolff D., Zhang K.K., He W.W., Sun X.H., Lu Y., Zhou P. Molecular Inflammation in the Contralateral Eye after Cataract Surgery in the First Eye. Invest Ophthalmol Vis Sci. 2015;56(9):5566–5573. DOI:10.1167/iovs.15-16531; Weber K.S., Nelson P.J., Grone H.J., Weber C. Expression of CCR2 by endothelial cells: implications for MCP-1 mediated wound injury repair and In vivo inflammatory activation of endothelium. Arterioscler Thromb Vasc Biol. 1999;19:2085–2093.; Kawai M., Inoue T., Inatani M., Tsuboi N., Shobayashi K., Matsukawa A., Yoshida A., Tanihara H. Elevated levels of monocyte chemoattractant protein-1 in the aqueous humor after phacoemulsification. Invest Ophthalmol Vis Sci. 2012;53(13):7951–7960. DOI:10.1167/iovs.12-10231; Zelova H., Hosek J. TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res. 2013;62(7):641–651. DOI:10.1007/s00011-013-0633-0; Chu L., Wang B., Xu B., Dong N. Aqueous cytokines as predictors of macular edema in non-diabetic patients following uncomplicated phacoemulsification cataract surgery. Mol Vis. 2013;19:2418–2425.; Dong N., Xu B., Wang B., Chu L., Tang X. Aqueous cytokines as predictors of macular edema in patients with diabetes following uncomplicated phacoemulsification cataract surgery. Biomed Res Int. 2015;2015:1–8. DOI:10.1155/2015/126984; Palomo J., Dietrich D., Martin P., Palmer G., Gabay C. The interleukin (IL)-1 cytokine family-Balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015;76(1):25–37. DOI:10.1016/j.cyto.2015.06.017; Baptista F.I., Aveleira C.A., Castilho A.F., Ambrosio A.F. Elevated Glucose and Interleukin-1β Differentially Affect Retinal Microglial Cell Proliferation. Mediators Inflamm. 2017;2017:1–11. DOI:10.1155/2017/4316316; Noma H. Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion. Retina. 2012;32(1):86–91. DOI:10.1097/IAE.0b013e31821801de; Koss M. J., Pfister M., Rothweiler F. Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion. Acta Ophthalmol. 2012;90(2):98–103. DOI:10.1111/j.1755-3768.2011.02292.x; Saravia M., Zeman L., Ingolotti M., Schlaen A. The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration? Med Hypotheses. 2017;109:156–161. DOI:10.1016/j.mehy.2017.10.001; Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol. 2011;29:71–109. DOI:10.1146/annurev-immunol-031210-101312; Endo N., Kato S., Haruyama K., Shoji M., Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010;88(8):896–900. DOI:10.1111/j.1755-3768.2009.01582.x; Singh R., Alpern L., Jaffe G.J., Lehmann R.P., Lim J., Reiser H.J., Sall K., Walters T., Sager D. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259–1269. DOI:10.2147/OPTH.S31902; Wielders L.H.P., Schouten J.S.A.G., Nuijts R.M.M.A. Prevention of macular edema after cataract surgery. Curr Opin Ophthalmol. 2018;29(1):48–53. DOI:10.1097/ICU.0000000000000436; Chew E.Y., Glassman A.R., Beck R.W., Bressler N.M., Fish G.E., Ferris F.L., Kinyoun J.L. Ocular Side Effects Associated with Peribulbar Injections of Triamcinolone Acetonide for Diabetic Macular Edema. Retina. 2011;31(2):284–289. DOI:10.1097/IAE.0b013e3181f049a8; Zhang Y.P, Peng X.Y., Li Z.H., Chen F.H. Hyperglycemic effects of a periocular dexamethasone injection in diabetic patients after vitreoretinal surgery. Biomed Environ Sci. 2012;25(3):311–316. DOI:10.3967/0895-3988.2012.03.009; Udaondo P., Garcia-Pous M., Garcia-Delpech S., Salom D., Diaz-Llopis M. Prophylaxis of macular edema with intravitreal ranibizumab in patients with diabetic retinopathy after cataract surgery: a pilot study. J Ophthalmol. 2011;2011:1–4. DOI:10.1155/2011/159436; Chae J.B., Joe S.G., Yang S.J., Lee J.Y., Sung K.R., Kim J.Y., Kim J.G., Yoon Y.H. Effect of combined cataract surgery and ranibizumab injection in postoperative macular edema in nonproliferative diabetic retinopathy. Retina. 2014;34(1):149–156. DOI:10.1097/IAE.0b013e3182979b9e; Pollack A., Staurenghi G., Sager D., Mukesh B., Reiser H., Singh R.P. Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1 % treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2017;101(4):423–427. DOI:10.1136/bjophthalmol-2016-308617; Sarfraz M.H., Haq R.I., Mehboob M.A. Effect of topical nepafenac in prevention of macular edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Pak J Med Sci. 2017;33(1):210–214. DOI:10.12669/pjms.331.11644; https://www.ophthalmojournal.com/opht/article/view/773

  20. 20